Comparing the current results to its competitors, Phathom Pharmaceuticals Inc reported Revenue increase in the 1 quarter 2026 by 104.43 % year on year. The sales growth was above Phathom Pharmaceuticals Inc 's competitors' average revenue growth of 12.93 %, achieved in the same quarter.
Phathom Pharmaceuticals Inc , slower than the average decrease reported by the company's competitors of -51.58 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -51.58 %
Due to outstanding performance in Overall company, revenue grew by 104.43 % Phathom Pharmaceuticals Inc improved its market share, to approximately 0.38 %.
December 11, 2024
Phathom Pharmaceuticals, Inc. a biopharmaceutical company focused on advancing novel treatments for gastrointestinal (GI) diseases, has taken a decisive step to protect its innovative drug, VOQUEZNA (vonoprazan), by submitting a Citizen Petition (CP) to the U.S. Food and Drug Administration (FDA). Announced on December 11, 2024, the petition requests a revision in the Orange Book listings for its 10 mg and 20 mg tablet formulations of VOQUEZNA to ensure the full 10-year New Chemical Entity (NCE) exclusivity is applied, projecting extended exclusivity until May 3, 2032.The Citizen Petition represents Phathom Pharmaceuticals efforts to safeguard its intellectual property rights concerning VOQUEZNA, a drug ind...
May 15, 2024
Phathom Pharmaceuticals to Present Groundbreaking Data on VOQUEZNA (vonoprazan) at DDW 2024 Annual MeetingFLORHAM PARK, N.J., May 15, 2024 - Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a leading biopharmaceutical company specializing in the development and commercialization of innovative treatments for gastrointestinal (GI) diseases, has recently unveiled plans to showcase significant findings from multiple studies on its groundbreaking treatment, VOQUEZNA (vonoprazan), at the prestigious Digestive Disease Week (DDW) 2024. The event is scheduled to take place in Washington, D.C., from May 18 to 21.Phathom Pharmaceuticals is dedicated to addressing the unmet medical needs of patients suffering from various ...
Publicly Traded Peers of Phathom Pharmaceuticals Inc
Agios Pharmaceuticals Inc Share Performance
+25.57%
This Year
Agios Pharmaceuticals Inc
Profile
Agios Pharmaceuticals Inc is a biopharmaceutical company that focuses on researching and developing innovative therapies for treating genetic diseases and cancer.
Diamedica Therapeutics Inc's business model focuses on developing and commercializing innovative therapies to improve patient outcomes in areas of unmet medical needs.
Evolus Inc is a pharmaceutical company that operates in the field of aesthetics, with a primary focus on developing and commercializing minimally invasive treatments for patients. Their business model revolves around researching and developing innovative neurotoxin products to address various facial aesthetic concerns. The company aims to bring their products to market through strategic partnerships with healthcare professionals and providers, ensuring widespread accessibility and utilization.
Galmed Pharmaceuticals Ltd's business model focuses on the development and commercialization of innovative therapeutic solutions, particularly in the field of liver and metabolic diseases.
Ironwood Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of medicines for gastrointestinal disorders. Their business model involves discovering, developing, and marketing innovative treatments for conditions like irritable bowel syndrome and chronic constipation. They aim to achieve growth and profitability by leveraging their research capabilities and collaborating with strategic partners in the healthcare industry.
Sources:
Phathom Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Phathom Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
